CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2022	Apr. 30, 2021
Income Statement [Abstract]
Oncology services revenue	$ 49,109	$ 41,040
Costs and operating expenses:
Cost of oncology services	23,632	21,446
Research and development	9,374	7,196
Sales and marketing	6,379	5,520
General and administrative	9,117	6,512
Total costs and operating expenses	48,502	40,674
Income from operations	607	366
Other expense:
Other income (expense), net	(24)	71
Income before income tax expense	583	437
Provision for income tax	35	75
Net income	$ 548	$ 362
Net income per common share outstanding
Net income per common share outstanding, basic (in usd per share)	$ 0.04	$ 0.03
Net income per common share outstanding, diluted (in usd per share)	$ 0.04	$ 0.02
Weighted average common shares outstanding
Weighted average common shares outstanding basic (in shares)	13,197,170	13,138,995
Weighted average common shares outstanding diluted (in shares)	14,159,799	14,573,561
Revenue, Product and Service [Extensible Enumeration]	Service [Member]	Service [Member]
Cost, Product and Service [Extensible Enumeration]	Service [Member]	Service [Member]